NASDAQConsumer DiscretionaryFurnishings, Fixtures & AppliancesSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for KEQU yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
EPS at or above $3.43 next fiscal year | Analysts expect revenue growth around 8% next year. | Intact | EPS guidance falls below $3.43 for fiscal year 2027 | Diluted EPS: $0.58 per share FY2027-Q1; GAAP. Published target: >=3.43 USD_PER_SHARE. Target period ends 2027-04-30; this observation covers 2027-Q1. Sep 11, 20260.58 USD/share · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 7–Nov 5 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Dec 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
KEQU is a growth-oriented, acquisition-supported business with a multi-year thesis that is intact but not yet steady. Fiscal 2026 growth and progress integrating Nu Aire support the longer view, while recent quarterly revenue softness and a record of recent misses make the near-term setup riskier.
The valuation signal is mixed: KEQU is described as cheap versus peers, while the peer comparison also shows a 0.77 premium and the expectations gap is negative. The priced-in assessment calls expectations justified and finds low fragility, so the evidence does not point to a clear excess-expectations cushion.
Management has maintained its focus on disciplined growth and Nu Aire integration, with fiscal 2026 revenue growth and Lab Products Group growth showing progress. Near term, revenue fell between 2026-Q1 and 2027-Q1, and the next results carry elevated risk given recent misses; debt reduction is progressing but remains a watch item.
A guidance cut at the next call would be a meaningful negative, while continued earnings strength and higher guidance from sector bellwethers could support the sector backdrop. Misses or weaker guidance from those companies could remove that support; KEQU’s own execution and integration progress also matter to the multi-year thesis.
Over the next 1 to 3 years, growth execution and Nu Aire integration support an intact thesis, but mixed recent results and elevated near-term risk leave important questions around consistency. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Free cash flow yield is strong at 14%, supporting financial health. |
| Broken |
| Free cash flow yield falls below 10% |
Free cash flow yield: 10.92% As of 2026-11-05; trailing twelve months. The target timing and basis require a separate assessment. Nov 5, 202610.92 percent · calculatedLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth near 8% next year | Analysts expect revenue growth around 8% next year. | Intact | Revenue growth falls below 6% YoY next year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.